Erastin: Precision Ferroptosis Inducer for Cancer Biology Research

Executive Summary: Erastin (CAS 571203-78-6) is a small molecule that reliably induces ferroptosis, a distinct form of iron-dependent, caspase-independent cell death, in tumor cells with RAS or BRAF mutations (Dong et al., 2023). It acts through inhibition of the cystine/glutamate antiporter system Xc⁻ and modulation of the voltage-dependent anion channel (VDAC) (APExBIO product spec). Erastin increases intracellular reactive oxygen species (ROS), leading to lethal oxidative damage (ECL Chemiluminescent, 2023). It is not effective in apoptosis-resistant cells unless they rely on redox homeostasis for survival. APExBIO's Erastin (SKU B1524) is a validated standard for ferroptosis research and oxidative stress assays.

Biological Rationale

Ferroptosis is a regulated cell death pathway, distinct from apoptosis and necrosis, defined by iron dependency and accumulation of lipid peroxides (Dong et al., 2023). Cancer cells with mutations in the RAS family (HRAS, KRAS) or BRAF genes exhibit heightened sensitivity to oxidative stress due to altered redox homeostasis. System Xc⁻ (SLC7A11/SLC3A2) imports cystine in exchange for glutamate, supplying cysteine for glutathione synthesis, which is critical for detoxifying ROS. Inhibiting this pathway reduces glutathione, making cells susceptible to ferroptosis.

Mechanism of Action of Erastin

Erastin induces ferroptosis by two converging mechanisms:

• Inhibition of system Xc⁻: Erastin blocks the cystine/glutamate antiporter, depleting intracellular cysteine and glutathione, thus impairing the cell's ability to neutralize ROS (APExBIO).
• VDAC modulation: Erastin binds and opens the mitochondrial VDAC, disrupting membrane potential and promoting oxidative damage.

This dual action leads to accumulation of lipid ROS and cell death that is iron-dependent and caspase-independent—hallmarks of ferroptosis. Erastin's specificity for RAS/BRAF-mutant tumor cells stems from their increased basal ROS and reliance on system Xc⁻ for redox balance.

Evidence & Benchmarks

• Knockdown of MCT4 increases sensitivity of bladder cancer 5637 cells to Erastin-induced ferroptosis by elevating ROS and lipid peroxidation (Dong et al., 2023).
• Erastin at 10 μM for 24 h induces significant cell death in HT-1080 fibrosarcoma cells, a standard model for ferroptosis (APExBIO).
• Erastin-induced ferroptosis is blocked by iron chelators (deferoxamine) or lipid peroxidation inhibitors (ferrostatin-1), confirming mechanism specificity (ECL Chemiluminescent).
• Erastin is ineffective in cells lacking system Xc⁻ expression, demonstrating pathway dependence (MutantIDH1-in-1).
• Erastin synergizes with autophagy inhibitors (e.g., chloroquine) to increase cell death in certain tumor contexts, suggesting interplay between ferroptosis and autophagy (Dong et al., 2023).

Applications, Limits & Misconceptions

Erastin is widely used in:

• Ferroptosis research: Confirming cell death modality in genetic or pharmacologic studies.
• Cancer biology: Elucidating vulnerabilities of RAS/BRAF-mutant tumors to oxidative stress.
• Oxidative stress assays: Dissecting redox homeostasis mechanisms.
• Drug synergy screens: Identifying compounds that sensitize or protect cells from ferroptosis.

For a comparative overview of Erastin's mechanistic underpinnings, see "Erastin: Precision Ferroptosis Inducer for Cancer Biology...", which details how Erastin enables advanced experimentation in redox biology; this article extends that discussion with updated evidence and workflow guidance.

More recent work on Erastin's translational promise is discussed in "Erastin and the Next Era of Ferroptosis Research: Strateg...", while this article provides practical parameters and clarifies mechanistic limits.

Common Pitfalls or Misconceptions

• Not all cell death is ferroptosis: Erastin-induced death is iron- and lipid peroxidation-dependent; confirmation requires use of specific inhibitors (e.g., ferrostatin-1).
• Apoptosis-resistant cells may still evade ferroptosis if they do not rely on system Xc⁻ or have alternative glutathione sources.
• Storage and solubility limitations: Erastin is unstable in solution over long periods; use freshly prepared DMSO solutions and avoid water or ethanol as solvents (APExBIO).
• Not effective in system Xc⁻-deficient cells: Tumors lacking SLC7A11/SLC3A2 expression are resistant.
• Not a clinical therapeutic: Erastin is a research tool, not an approved drug.

Workflow Integration & Parameters

• Compound preparation: Dissolve Erastin in DMSO at concentrations ≥10.92 mg/mL. Warm gently. Avoid water or ethanol.
• Storage: Store Erastin powder at -20°C. Prepare solutions fresh before use. Do not store solutions long-term.
• Cytotoxicity assay: Treat RAS/BRAF-mutant tumor cells (e.g., HT-1080) at 10 μM Erastin for 24 h. Include iron chelator and lipid peroxidation inhibitor controls.
• Redox/ROS measurement: Measure intracellular ROS (e.g., DCFDA assay) and lipid peroxidation (MDA assay) post-treatment.
• Genetic context: Confirm status of RAS/BRAF mutations and system Xc⁻ expression for optimal model selection.

For further methodological updates and clinical translation strategies, see "Erastin and the Evolving Frontier of Ferroptosis: Mechani...", which this article updates by providing precise workflow integration and reagent handling guidance.

To purchase or learn more about the validated research specification, visit the APExBIO Erastin B1524 product page.

Conclusion & Outlook

Erastin is a benchmark ferroptosis inducer for the study of iron-dependent, non-apoptotic cell death in cancer biology. Its mechanism—system Xc⁻ inhibition and VDAC modulation—enables rigorous interrogation of redox vulnerabilities, especially in RAS/BRAF-mutant tumors. While not a clinical therapeutic, Erastin (B1524, APExBIO) remains essential for dissecting ferroptosis and guiding future drug development. As mechanistic understanding and translational tools improve, Erastin will continue to inform the evolving frontier of cancer therapy targeting ferroptosis.